[go: up one dir, main page]

MX2022016498A - Una combinacion de un inhibidor de cbp/p300 bromodominio y un inhibidor de kras. - Google Patents

Una combinacion de un inhibidor de cbp/p300 bromodominio y un inhibidor de kras.

Info

Publication number
MX2022016498A
MX2022016498A MX2022016498A MX2022016498A MX2022016498A MX 2022016498 A MX2022016498 A MX 2022016498A MX 2022016498 A MX2022016498 A MX 2022016498A MX 2022016498 A MX2022016498 A MX 2022016498A MX 2022016498 A MX2022016498 A MX 2022016498A
Authority
MX
Mexico
Prior art keywords
inhibitor
kras
cbp
cancer
treatment
Prior art date
Application number
MX2022016498A
Other languages
English (en)
Inventor
Thomas Bohnacker
Martin Schwill
Stefanie Flückiger-Mangual
Dorothea Gruber
Debora Schmitz-Rohmer
Charles- Henry Fabritius
Sara Laudato
Original Assignee
Tolremo Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tolremo Therapeutics Ag filed Critical Tolremo Therapeutics Ag
Publication of MX2022016498A publication Critical patent/MX2022016498A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere, entre otras cosas, a (i) una combinación de un inhibidor del bromodominio CBP/p300 y un inhibidor de KRAS para su uso en el tratamiento de un paciente que padece cáncer, en donde el cáncer presenta una alteración oncogénica en el KRAS; (ii) un kit que comprende (a) una forma farmacéutica de dosificación que comprende un inhibidor del bromodominio CBP/p300 y (b) una forma farmacéutica de dosificación que comprende un inhibidor de KRAS; y (iii) una forma farmacéutica de dosificación que comprende un inhibidor del bromodominio CBP/p300 y un inhibidor de KRAS.
MX2022016498A 2020-06-25 2021-06-24 Una combinacion de un inhibidor de cbp/p300 bromodominio y un inhibidor de kras. MX2022016498A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20182364 2020-06-25
PCT/EP2021/067349 WO2021260111A1 (en) 2020-06-25 2021-06-24 Combination of a cbp/p300 bromodomain inhibitor and a kras inhibitor for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2022016498A true MX2022016498A (es) 2023-02-23

Family

ID=71170341

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016498A MX2022016498A (es) 2020-06-25 2021-06-24 Una combinacion de un inhibidor de cbp/p300 bromodominio y un inhibidor de kras.

Country Status (11)

Country Link
US (1) US12472179B2 (es)
EP (1) EP4171557A1 (es)
JP (1) JP2023533464A (es)
KR (1) KR20230028798A (es)
CN (1) CN115996717A (es)
AU (1) AU2021298154A1 (es)
BR (1) BR112022026186A2 (es)
CA (1) CA3184076A1 (es)
IL (1) IL299344A (es)
MX (1) MX2022016498A (es)
WO (1) WO2021260111A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114728934B (zh) 2019-10-02 2024-08-27 托雷莫治疗股份公司 杂环衍生物、药物组合物和它们治疗或改善癌症的用途
EP4204412A4 (en) * 2020-08-26 2024-10-09 InventisBio Co., Ltd. HETEROARYL COMPOUNDS, PRODUCTION PROCESSES AND USES THEREOF
WO2022214102A1 (zh) * 2021-04-09 2022-10-13 杭州英创医药科技有限公司 作为kras g12d抑制剂的杂环化合物
US20240374597A1 (en) * 2021-07-29 2024-11-14 Board Of Regents, The University Of Texas System Methods and compositions for treatment of kras mutant cancer
CN118742544A (zh) * 2022-02-07 2024-10-01 基因泰克公司 1-((s)-4-((r)-7-(6-氨基-4-甲基-3-(三氟甲基)吡啶-2-基)-6-氯-8-氟-2-(((s)-1-甲基吡咯烷-2-基)甲氧基)喹唑啉-4-基)-3-甲基哌嗪-1-基)丙-2-烯-1-酮的固体形式
EP4497751A4 (en) * 2022-03-22 2026-02-18 Suzhou Zelgen Biopharmaceuticals Co Ltd SUBSTITUTED BRIDGED CYCLE INHIBITOR, ITS PREPARATION PROCESS AND ITS USE
WO2023229535A1 (en) * 2022-05-27 2023-11-30 Engine Biosciences Pte. Ltd. Bet polypeptide therapeutic agents for generating synthetic lethality in tumors
CN120152970A (zh) * 2022-10-03 2025-06-13 普莱鲁德疗法有限公司 使用smarca2降解剂和kras靶向疗法的组合实现的癌症治疗
WO2024229406A1 (en) * 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
ATE12348T1 (de) 1980-11-10 1985-04-15 Gersonde Klaus Prof Dr Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens.
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0142641B1 (de) 1983-09-26 1991-01-16 Udo Dr. Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
NZ503464A (en) 1997-09-29 2002-05-31 Inhale Therapeutic Syst Perforated microparticles containing a bioactive agent for pulmonary delivery
EP1034826A1 (en) 1999-03-05 2000-09-13 Reuter Chemische Apparatebau Co-crystallization process
JP2001089452A (ja) 1999-09-22 2001-04-03 Sankyo Co Ltd ピリミジン誘導体
EP1280520B2 (en) 2000-05-10 2018-03-21 Novartis AG Phospholipid-based powders for drug delivery
CA2422367C (en) 2000-09-15 2010-05-18 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ATE508735T1 (de) 2001-12-19 2011-05-15 Novartis Ag Pulmonale verabreichung von aminoglykosiden
CA2562602A1 (en) 2004-04-15 2005-10-27 Astellas Pharma Inc. 2-aminopyridine derivative
PL2044056T3 (pl) 2006-07-14 2013-01-31 Novartis Ag Pochodne pirymidyny jako inhibitory ALK-5
CA2703037A1 (en) 2007-10-17 2009-04-23 Novartis Ag Organic compounds
WO2011085039A2 (en) 2010-01-05 2011-07-14 The Johns Hopkins University Use of histone acetyltransferase inhibitors as novel anti-cancer therapies
WO2013148114A1 (en) 2012-03-30 2013-10-03 University Of Florida Research Foundation, Inc. P300/cbp inhibitors and methods of use
TW201414737A (zh) 2012-07-13 2014-04-16 必治妥美雅史谷比公司 作爲激酶抑制劑之咪唑并三□甲腈
CA2904048A1 (en) * 2013-03-11 2014-10-09 Abbvie Inc. Bromodomain inhibitors
WO2014177524A1 (en) 2013-05-01 2014-11-06 F. Hoffmann-La Roche Ag C-linked heterocycloalkyl substituted pyrimidines and their uses
CA2926946A1 (en) 2013-10-11 2015-04-16 Genentech, Inc. Use of cbp/ep300 bromodomain inhibitors for cancer immunotherapy
JP6474166B2 (ja) 2014-01-01 2019-02-27 メディベイション テクノロジーズ エルエルシー 化合物及び使用方法
CN107223125B (zh) 2014-09-17 2019-09-27 赛科理音医疗有限公司 sGC刺激剂
WO2016123054A2 (en) 2015-01-26 2016-08-04 The University Of North Carolina At Chapel Hill Kinase drug combinations and methods of use thereof
CN106146508A (zh) 2015-03-19 2016-11-23 浙江导明医药科技有限公司 优化的联合用药及其治疗癌症和自身免疫疾病的用途
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
EP3302465A1 (en) 2015-06-05 2018-04-11 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
AU2016304856B8 (en) * 2015-08-10 2021-02-18 Dana-Farber Cancer Institute, Inc. Mechanism of resistance to BET bromodomain inhibitors
JP2019500368A (ja) * 2015-12-17 2019-01-10 ギリアード サイエンシーズ， インコーポレイテッド Ｔａｎｋ結合キナーゼ阻害剤化合物
WO2017120446A1 (en) 2016-01-08 2017-07-13 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
EA201990370A1 (ru) 2016-07-25 2019-06-28 Эпизайм, Инк. Терапия рака, связанная с crebbp
GB201617630D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
JP2020517618A (ja) 2017-04-21 2020-06-18 エピザイム，インコーポレイティド Ｅｈｍｔ２阻害剤との併用療法
IT201700047189A1 (it) 2017-05-02 2018-11-02 Fondazione St Italiano Tecnologia Composti e composizioni per il trattamento di cancro, disordini della retina e cardiomiopatie
JOP20190272A1 (ar) * 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
CA3065365C (en) 2017-05-30 2025-09-16 Deciphera Pharmaceuticals, Llc USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDINE-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ITS ANALOGUES FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN THE PLATELET-DERIVED GROWTH FACTOR ALPHA RECEPTOR
AU2018311523A1 (en) 2017-08-03 2020-01-16 Novartis Ag Therapeutic combination of a third-generation EGFR tyrosine kinase inhibitor and a Raf inhibitor
EP3661519A1 (en) 2017-08-03 2020-06-10 Novartis AG Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
WO2019045824A1 (en) 2017-09-01 2019-03-07 Kadmon Corporation, Llc ALPHA PROPELLER PROTEIN KINASE INHIBITORS ("COILED-COIL") ASSOCIATED WITH RHO
CA3082579A1 (en) * 2017-11-15 2019-05-23 Mirati Therapeutics, Inc. Kras g12c inhibitors
AU2018368639B2 (en) 2017-11-20 2025-02-27 Tolremo Therapeutics Ag Diagnostic method
KR102141697B1 (ko) * 2017-11-23 2020-08-05 한국과학기술원 PI3K/mTOR 저해제 저항성 암 치료제
GB201806320D0 (en) 2018-04-18 2018-05-30 Cellcentric Ltd Process
WO2020006483A1 (en) 2018-06-29 2020-01-02 Forma Therapeutics, Inc. Inhibiting creb binding protein (cbp)
WO2020023768A1 (en) 2018-07-25 2020-01-30 Mayo Foundation For Medical Education And Research Methods and materials for identifying and treating bet inhibitor-resistant cancers
CN112566907A (zh) 2018-08-17 2021-03-26 南京明德新药研发有限公司 作为ret抑制剂的吡唑衍生物
CA3111980A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
US12336995B2 (en) 2018-09-10 2025-06-24 Mirati Therapeutics, Inc. Combination therapies
ES3004338T3 (en) * 2018-09-10 2025-03-12 Mirati Therapeutics Inc Combination therapies
PL3849534T3 (pl) 2018-09-10 2025-05-12 Mirati Therapeutics, Inc. Połączenie dazatynibu i adagrasibu do stosowania w leczeniu niedrobnokomórkowego raka płuca
MX2021002804A (es) 2018-12-05 2021-07-15 Mirati Therapeutics Inc Terapias de combinacion.
AU2019407650B2 (en) 2018-12-17 2022-10-27 Tolremo Therapeutics Ag Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
CN114728934B (zh) 2019-10-02 2024-08-27 托雷莫治疗股份公司 杂环衍生物、药物组合物和它们治疗或改善癌症的用途
CA3160142A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
CA3176957A1 (en) 2020-03-27 2021-09-30 Dong-A St Co., Ltd. Aminopyrimidine derivatives and their use as aryl hydrocarbon receptor modulators
AU2021295432A1 (en) 2020-06-25 2023-02-23 Tolremo Therapeutics Ag Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease
JP2023532675A (ja) 2020-06-25 2023-07-31 トルレモ・セラピューティクス・アクチェンゲゼルシャフト ＥＧＦＲ突然変異ＮＳＣＬＣの治療に使用するための、ＣＢＰ／ｐ３００ブロモドメイン阻害剤およびＥＧＦＲ阻害剤の組合せ

Also Published As

Publication number Publication date
WO2021260111A1 (en) 2021-12-30
US12472179B2 (en) 2025-11-18
EP4171557A1 (en) 2023-05-03
IL299344A (en) 2023-02-01
CN115996717A (zh) 2023-04-21
AU2021298154A1 (en) 2023-02-23
CA3184076A1 (en) 2021-12-30
BR112022026186A2 (pt) 2023-01-17
US20230233558A1 (en) 2023-07-27
JP2023533464A (ja) 2023-08-03
KR20230028798A (ko) 2023-03-02

Similar Documents

Publication Publication Date Title
MX2022016498A (es) Una combinacion de un inhibidor de cbp/p300 bromodominio y un inhibidor de kras.
AU2021408129A1 (en) Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor for the treatment of cancers
AU2019384119A8 (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
AU2022299651A9 (en) Pharmaceutical combinations comprising a kras g12c inhibitor and uses thereof for the treatment of cancers
MX2022006986A (es) Inhibidores de kras g12c.
MX2025003821A (es) Compuestos con actividad contra tumores mutantes de kras
CR20240144A (es) Inhibidores de parp1 de azetidina y pirrolidina y usos de estos
MX2021007970A (es) Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo.
MX2022016496A (es) Combinacion de un inhibidor del bromodominio cbp/p300 y un inhibidor del egfr para su uso en el tratamiento de la cpnm con mutacion del egfr.
MX2024013195A (es) Inhibidores de parp1 triciclicos y usos de estos
NO20074109L (no) Intravenose formuleringer av PDE-5 inhibitorer
GEAP202516662A (en) Anti-nectin-4 antibody, conjugate including same, and application thereof
MX2021000726A (es) Terapia combinada de gen de activacion de linfocitos 3(lag-3) para el tratamiento del cancer.
MX2024005107A (es) Nuevo uso de compuesto de quinazolinona para el tratamiento de cancer.
MX2025008092A (es) Inhibidores de kif18a y usos de los mismos
WO2023046060A8 (zh) 治疗kras突变的癌症患者
MX2024004214A (es) Combinaciones de inhibidores de kras g12d con irinotecán y métodos de tratamiento relacionados.
MX2025001990A (es) Agente terapeutico y metodo terapeutico que son para pacientes con cancer que presentan deterioro funcional de la proteina del retinoblastoma (rb1) y que implican el uso concomitante de inhibidor del factor de transcripcion 1 de mielina (myt1) y agente quimioterapeutico
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
MX2024015988A (es) Inhibidores terapeuticos de la tirosina cinasa para la esclerosis multiple y la miastenia grave
RU2020108631A (ru) Новая вспомогательная терапия для применения в способе лечения рака простаты
MX2022008532A (es) Inhibidores de hidrocarburo de arilo (ahr) y usos de estos.
MX2021005936A (es) Metodos farmaceuticos.
MX2021003274A (es) Combinacion farmaceutica para el tratamiento de cancer.
WO2023166492A3 (en) Dual inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy